{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:13:37Z","timestamp":1793643217175,"version":"4.5.1"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Treatment effects in the urinary bladder are variable and range from localized post-transurethral resection changes to widespread systemic therapy effects. The International Society of Urological Pathology (ISUP) organized a consensus meeting in Vienna, Austria, in September 2025, focused on the evaluation of treatment effects in both the prostate and bladder. Working Group 2 was assigned the topic of the urinary bladder, and a group of pathologists and clinicians was convened. They worked cooperatively to develop a 30-question, premeeting survey for the ISUP membership, which covered the following topics: systemic therapy\u2013related changes, intravesical therapy and radiotherapy-related changes, macroscopic examination and reporting of treated bladder specimens, and relevant ancillary testing methods for grossly residual and\/or minimal residual disease. The premeeting survey results highlighted uncertainty about tumor regression grading (TRG), variability in reporting practices for post-resection and intravesical therapy cases, and divergent opinions on the potential utility of molecular testing. Based on findings from this crowd-sourced experience, the Working Group researched the primary medical literature to study the problematic premeeting survey topics, curated focused presentations of published experience for the consensus meeting participants and developed refined consensus questions for consensus voting. Consensus was achieved in 18\/19 polling statements. Use of molecular tests to distinguish benign mimickers from carcinoma did not reach consensus. Overall, the surveys and in-person consensus voting supported standardized reporting practices and terminology for post-therapy cases, interdisciplinary development of a bladder TRG scheme, and the utility of select molecular and immunohistochemical testing in the post-treatment setting.<\/jats:p>","DOI":"10.1097\/pas.0000000000002613","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:00:10Z","timestamp":1788336010000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["International Society of Urological Pathology Multidisciplinary Expert Consultation Conference on Evaluation of Treatment Effects in Prostate and Bladder Cancer"],"prefix":"10.1097","author":[{"given":"Michelle R.","family":"Downes","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Molecular Diagnostics, Division of Anatomic Pathology, Precision Diagnostics and Therapeutics Program, Sunnybrook Health Sciences Centre"},{"name":"Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Wobker","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine and Lineberger Comprehensive Cancer Center and University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU)"},{"name":"Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg"},{"name":"Bavarian Center for Cancer Research (BZKF), Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"Akgul","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek E.","family":"Baydar","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Research Center for Translational Medicine (KUTTAM), Koc University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Brimo","sequence":"additional","affiliation":[{"name":"McGill University Health Center, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Comp\u00e9rat","sequence":"additional","affiliation":[{"name":"Department of Pathology, Medical University of Vienna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandi","family":"Lobo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kapoor Centre of Urology and Pathology, Raipur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Raspollini","sequence":"additional","affiliation":[{"name":"Histopathology and Molecular Diagnostics, University Hospital Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur R.","family":"Sangoi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford Medical Center, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Southwestern, Dallas, TX"},{"name":"Department of Urology, Weill Cornell Medical College, New York, NY"},{"name":"Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria"},{"name":"Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University, School of Medicine, Nagakute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W. G.","family":"van Rhijn","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital"},{"name":"Netherlands Cancer Institute, Amsterdam"},{"name":"Department of Urology, Leiden University Medical Center, Leiden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean R.","family":"Williamson","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert J. L. H.","family":"van Leenders","sequence":"additional","affiliation":[{"name":"Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"},{"name":"Department of Surgery (Urology), Brown University Warren Alpert Medical School, Legorreta Cancer Center at Brown University, Brown University Health, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lopez-Beltran","sequence":"additional","affiliation":[{"name":"Department of Morphological Sciences, University of Cordoba Medical School, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Members of ISUP GU Cancer Treatment Effects Consensus Panel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"R1-20260902","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/ajcp\/aqad176","article-title":"Current gross examination and reporting patterns of post-neoadjuvant chemotherapy cystectomy specimens: is it time for a standardized approach?","volume":"161","author":"Saunders","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"R2-20260902","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00428-024-03924-3","article-title":"Variation in cystectomy pathology reporting practice-results from an international survey of 212 pathologists","volume":"485","author":"Griffin","year":"2024","journal-title":"Virchows Arch"},{"key":"R3-20260902","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/PAS.0000000000000142","article-title":"Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival","volume":"38","author":"Fleischmann","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R4-20260902","doi-asserted-by":"crossref","first-page":"34 e17","DOI":"10.1016\/j.urolonc.2016.08.005","article-title":"Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: is therapeutic effect owing to chemotherapy or TURBT?","volume":"35","author":"Brant","year":"2017","journal-title":"Urol Oncol"},{"key":"R5-20260902","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.humpath.2016.02.011","article-title":"Neoadjuvant chemotherapy-related histologic changes in radical cystectomy: assessment accuracy and prediction of response","volume":"53","author":"Wang","year":"2016","journal-title":"Hum Pathol"},{"key":"R6-20260902","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/his.13654","article-title":"Prognostic pathological factors in radical cystectomy after neoadjuvant chemotherapy","volume":"73","author":"Brimo","year":"2018","journal-title":"Histopathology"},{"key":"R7-20260902","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol"},{"key":"R8-20260902","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.annonc.2026.01.011","article-title":"Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant trials (PATHdata): results of a Society for Immunotherapy of Cancer multi-institutional reproducibility study","volume":"37","author":"Deutsch","year":"2026","journal-title":"Ann Oncol"},{"key":"R9-20260902","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/ajcp\/aqae167","article-title":"Urothelial carcinoma in situ with \u201cearly papillary formation\u201d vs \u201clateral spread\/shoulder lesion\u201d of prior high-grade noninvasive papillary urothelial carcinoma: a survey of pathologist and urologist interpretations","volume":"163","author":"Sangoi","year":"2025","journal-title":"Am J Clin Pathol"},{"key":"R10-20260902","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.semdp.2018.03.001","article-title":"Iatrogenic pathology of the urinary bladder","volume":"35","author":"Lopez-Beltran","year":"2018","journal-title":"Semin Diagn Pathol"},{"key":"R11-20260902","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/PAP.0000000000000226","article-title":"Iatrogenic disease of the genitourinary tract","volume":"26","author":"Cathro","year":"2019","journal-title":"Adv Anat Pathol"},{"key":"R12-20260902","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/his.13090","article-title":"Iatrogenic changes in the urinary tract","volume":"70","author":"Lopez-Beltran","year":"2017","journal-title":"Histopathology"},{"key":"R13-20260902","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/PAS.0000000000000238","article-title":"Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R14-20260902","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/PAS.0000000000000240","article-title":"Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference","volume":"38","author":"Amin","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R15-20260902","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/PAS.0000000000000114","article-title":"Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20\/CD44s\/p53) and alpha-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia","volume":"37","author":"Aron","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R16-20260902","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.humpath.2012.08.011","article-title":"Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases","volume":"44","author":"Oliva","year":"2013","journal-title":"Hum Pathol"},{"key":"R17-20260902","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.humpath.2020.02.008","article-title":"Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap","volume":"98","author":"Nguyen","year":"2020","journal-title":"Hum Pathol"},{"key":"R18-20260902","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13000-020-00984-2","article-title":"CK20 versus AMACR and p53 immunostains in evaluation of urothelial carcinoma in situ and reactive atypia","volume":"15","author":"Neal","year":"2020","journal-title":"Diagn Pathol"},{"key":"R19-20260902","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.acuro.2022.02.004","article-title":"A systematic review and meta-analysis of CK20, CD44, Ki67 and p53 as immunohistochemical markers in bladder carcinoma in situ","volume":"46","author":"Straccia","year":"2022","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"R20-20260902","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41379-022-01062-2","article-title":"p53 null phenotype is a \u201cpositive result\u201d in urothelial carcinoma in situ","volume":"35","author":"Sangoi","year":"2022","journal-title":"Mod Pathol"},{"key":"R21-20260902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2019.04.018","article-title":"Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical","volume":"90","author":"Pederzoli","year":"2019","journal-title":"Hum Pathol"},{"key":"R22-20260902","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/hupa.2000.7894","article-title":"Radiation-induced pseudocarcinomatous proliferations of the urinary bladder: a report of 4 cases","volume":"31","author":"Baker","year":"2000","journal-title":"Hum Pathol"},{"key":"R23-20260902","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.juro.2013.09.019","article-title":"Radiation cystitis with pseudocarcinomatous urothelial hyperplasia","volume":"190","author":"Humphrey","year":"2013","journal-title":"J Urol"},{"key":"R24-20260902","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/PAS.0b013e3180eaa1dc","article-title":"Pseudocarcinomatous epithelial hyperplasia in the bladder unassociated with prior irradiation or chemotherapy","volume":"32","author":"Lane","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R25-20260902","doi-asserted-by":"crossref","first-page":"716","DOI":"10.5858\/arpa.2022-0125-OA","article-title":"Urine cytology findings in cases of pseudocarcinomatous urothelial hyperplasia of the bladder often represent a diagnostic challenge","volume":"147","author":"Velez Torres","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"R26-20260902","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.5858\/arpa.2014-0311-CC","article-title":"Pseudocarcinomatous hyperplasia of the urinary bladder","volume":"138","author":"Wu","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"R27-20260902","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.juro.2012.12.005","article-title":"Pseudocarcinomatous urothelial hyperplasia of the bladder: clinical findings and followup of 70 patients","volume":"189","author":"Kryvenko","year":"2013","journal-title":"J Urol"},{"key":"R29-20260902","doi-asserted-by":"crossref","first-page":"46","DOI":"10.21037\/tau.2018.10.19","article-title":"The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer","volume":"8","author":"Soria","year":"2019","journal-title":"Transl Androl Urol"},{"key":"R30-20260902","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.aju.2011.03.004","article-title":"Is \u2018second-look\u2019 (re-staging) transurethral resection of bladder tumours a new standard of care?","volume":"9","author":"Herr","year":"2011","journal-title":"Arab J Urol"},{"key":"R31-20260902","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.euf.2016.12.011","article-title":"Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"4","author":"Naselli","year":"2018","journal-title":"Eur Urol Focus"},{"key":"R32-20260902","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline: 2024 Amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"R33-20260902","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/01.pas.0000213367.41251.5d","article-title":"Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains","volume":"31","author":"Tamas","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R34-20260902","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/PAS.0000000000000798","article-title":"GATA3 positivity in benign radiated prostate glands: a potential diagnostic pitfall","volume":"41","author":"Wobker","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R35-20260902","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"R36-20260902","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"R37-20260902","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"R38-20260902","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"R39-20260902","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Klumper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R40-20260902","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Klumper","year":"2024","journal-title":"J Clin Oncol"},{"key":"R41-20260902","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1038\/s41467-017-02320-7","article-title":"Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"key":"R42-20260902","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.eururo.2022.10.020","article-title":"Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition","volume":"83","author":"Erlmeier","year":"2023","journal-title":"Eur Urol"},{"key":"R43-20260902","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/iju.70122","article-title":"PD-L1 and Ki-67 expression before and after neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"32","author":"Sasaki","year":"2025","journal-title":"Int J Urol"},{"key":"R44-20260902","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"R45-20260902","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"R46-20260902","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/PAS.0000000000000114","article-title":"Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20\/CD44s\/p53) and alpha-methylacyl-CoA-racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia","volume":"37","author":"Aron","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R48-20260902","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3390\/cancers18040623","article-title":"Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.","volume":"18","author":"Grier","year":"2026","journal-title":"Cancers (Basel)"},{"issue":"12","key":"R49-20260902","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/ng.3692","article-title":"Clonal evolution of chemotherapy-resistant urothelial carcinoma.","volume":"48","author":"Faltas","year":"2016","journal-title":"Nat Genet"},{"issue":"24","key":"R50-20260902","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","article-title":"TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.","volume":"73","author":"Kinde","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"R51-20260902","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/his.12920","article-title":"Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.","volume":"69","author":"Cheng","year":"2016","journal-title":"Histopathology"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:00:16Z","timestamp":1788336016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002613"}},"subtitle":["Working Group 2: The Urinary Bladder"],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":49,"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002613","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"2026-05-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}